Yonglin Chen1, Xinshou Ouyang1, Rafaz Hoque1, Irma Garcia-Martinez1, Muhammad Nadeem Yousaf1, Sarah Tonack2, Stefan Offermanns2, Laurent Dubuquoy3, Alexandre Louvet4, Philippe Mathurin4, Veronica Massey5, Bernd Schnabl6, Ramon Alberola Bataller7, Wajahat Zafar Mehal8. 1. Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520, USA. 2. Max-Planck-Institute for Heart and Lung Research, Department of Pharmacology, Ludwigstr. 43, 61231 Bad Nauheim, Germany; Medical Faculty, J.W. Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. 3. Unité INSERM 995, Faculté de Médecine, Lille, France. 4. Service des Maladies de l'appareil digestif, Hôpital Huriez, Lille, France; Unité INSERM 995, Faculté de Médecine, Lille, France. 5. School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. 6. Department of Medicine, University of California San Diego, La Jolla, CA, USA. 7. Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. 8. Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520, USA; USA West Haven Veterans Medical Center, West Haven, CT 06516, USA. Electronic address: wajahat.mehal@yale.edu.
Abstract
BACKGROUND & AIMS: Sterile inflammation resulting in alcoholic hepatitis (AH) occurs unpredictably after many years of excess alcohol intake. The factors responsible for the development of AH are not known but mitochondrial damage with loss of mitochondrial function are common features. Hcar2 is a G-protein coupled receptor which is activated by β-hydroxybutyrate (BHB). We aimed to determine the relevance of the BHB-Hcar2 pathway in alcoholic liver disease. METHODS: We tested if loss of BHB production can result in increased liver inflammation. We further tested if BHB supplementation is protective in AH through interaction with Hcar2, and analyzed the immune and cellular basis for protection. RESULTS: Humans with AH have reduced hepatic BHB, and inhibition of BHB production in mice aggravated ethanol-induced AH, with higher plasma alanine aminotransferase levels, increased steatosis and greater neutrophil influx. Conversely supplementation of BHB had the opposite effects with reduced alanine aminotransferase levels, reduced steatosis and neutrophil influx. This therapeutic effect of BHB is dependent on the receptor Hcar2. BHB treatment increased liver Il10 transcripts, and promoted the M2 phenotype of intrahepatic macrophages. BHB also increased the transcriptional level of M2 related genes in vitro bone marrow derived macrophages. This skewing towards M2 related genes is dependent on lower mitochondrial membrane potential (Δψ) induced by BHB. CONCLUSIONS: Collectively, our data shows that BHB production during excess alcohol consumption has an anti-inflammatory and hepatoprotective role through an Hcar2 dependent pathway. This introduces the concept of metabolite-based therapy for AH. LAY SUMMARY: Alcoholic hepatitis is a life-threatening condition with no approved therapy that occurs unexpectedly in people who consume excess alcohol. The liver makes many metabolites, and we demonstrate that loss of one such metabolite β-hydroxybutyrate occurs in patients with alcoholic hepatitis. This loss can increase alcohol-induced liver injury, and β-hydroxybutyrate can protect from alcohol-induced liver injury via a receptor on liver macrophages. This opens the possibility of metabolite-based therapy for alcoholic hepatitis.
BACKGROUND & AIMS: Sterile inflammation resulting in alcoholic hepatitis (AH) occurs unpredictably after many years of excess alcohol intake. The factors responsible for the development of AH are not known but mitochondrial damage with loss of mitochondrial function are common features. Hcar2 is a G-protein coupled receptor which is activated by β-hydroxybutyrate (BHB). We aimed to determine the relevance of the BHB-Hcar2 pathway in alcoholic liver disease. METHODS: We tested if loss of BHB production can result in increased liver inflammation. We further tested if BHB supplementation is protective in AH through interaction with Hcar2, and analyzed the immune and cellular basis for protection. RESULTS:Humans with AH have reduced hepatic BHB, and inhibition of BHB production in mice aggravated ethanol-induced AH, with higher plasma alanine aminotransferase levels, increased steatosis and greater neutrophil influx. Conversely supplementation of BHB had the opposite effects with reduced alanine aminotransferase levels, reduced steatosis and neutrophil influx. This therapeutic effect of BHB is dependent on the receptor Hcar2. BHB treatment increased liver Il10 transcripts, and promoted the M2 phenotype of intrahepatic macrophages. BHB also increased the transcriptional level of M2 related genes in vitro bone marrow derived macrophages. This skewing towards M2 related genes is dependent on lower mitochondrial membrane potential (Δψ) induced by BHB. CONCLUSIONS: Collectively, our data shows that BHB production during excess alcohol consumption has an anti-inflammatory and hepatoprotective role through an Hcar2 dependent pathway. This introduces the concept of metabolite-based therapy for AH. LAY SUMMARY:Alcoholic hepatitis is a life-threatening condition with no approved therapy that occurs unexpectedly in people who consume excess alcohol. The liver makes many metabolites, and we demonstrate that loss of one such metabolite β-hydroxybutyrate occurs in patients with alcoholic hepatitis. This loss can increase alcohol-induced liver injury, and β-hydroxybutyrate can protect from alcohol-induced liver injury via a receptor on liver macrophages. This opens the possibility of metabolite-based therapy for alcoholic hepatitis.
Authors: Johan L K Van Hove; Stephanie Grünewald; Jaak Jaeken; Philippe Demaerel; Peter E Declercq; Pierre Bourdoux; Klary Niezen-Koning; John E Deanfeld; James V Leonard Journal: Lancet Date: 2003-04-26 Impact factor: 79.321
Authors: Bing Luan; Young-Sil Yoon; John Le Lay; Klaus H Kaestner; Susan Hedrick; Marc Montminy Journal: Proc Natl Acad Sci U S A Date: 2015-12-07 Impact factor: 11.205
Authors: Vikrant R Mahajan; Sophie K Elvig; Leandro F Vendruscolo; George F Koob; Valerie L Darcey; M Todd King; Henry R Kranzler; Nora D Volkow; Corinde E Wiers Journal: Front Psychiatry Date: 2021-11-30 Impact factor: 5.435
Authors: María Del Carmen Blanco-Gandía; Francisco Ródenas-González; María Pascual; Marina Daiana Reguilón; Consuelo Guerri; José Miñarro; Marta Rodríguez-Arias Journal: Nutrients Date: 2021-06-24 Impact factor: 5.717